EyePoint Pharmaceuticals ...

5.30
0.25 (4.95%)
At close: Apr 02, 2025, 11:00 AM
4.95%
Bid 3.81
Market Cap 364.26M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.32
PE Ratio (ttm) -2.28
Forward PE -3.18
Analyst Buy
Ask 6.37
Volume 284,602
Avg. Volume (20D) 818,368
Open 5.00
Previous Close 5.05
Day's Range 4.92 - 5.32
52-Week Range 4.92 - 23.65
Beta 1.42

About EYPT

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 27, 2005
Employees 165
Stock Exchange NASDAQ
Ticker Symbol EYPT
Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 447.17% from the latest price.

Stock Forecasts

Next Earnings Release

EyePoint Pharmaceuticals Inc. is scheduled to release its earnings on May 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+2.36%
EyePoint Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
5 months ago
+27.58%
EyePoiint Pharmaceuticals shares are trading higher after the company showed early trial data for DURAVYU for diabetic macular edema and announced improving vision and anatomy.